Navigation Links
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
Date:6/6/2009

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today new, positive Phase II study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) analog administered subcutaneously once-weekly for the treatment of type 2 diabetes. These data will be presented as part of the American Diabetes Association's (ADA) 69th Annual Scientific Sessions.

In the Phase II study, known as GBCJ, LY2189265 was significantly superior to placebo in reducing key measures of glycemic control, including fasting serum glucose and hemoglobin A1C (HbA1C). In this study, LY2189265 showed an insulinotropic (stimulating the secretion of insulin) effect, suggesting it produced the desired outcome in participants. In Study GBCJ, LY2189265 was generally well-tolerated.

"We are excited about these data and the hope they could provide to the millions of diabetes patients who are struggling to maintain tight control of their blood glucose," said Pawel Fludzinski, Ph.D., global development leader for the GLP-1Fc team. "Evaluating the results of this study is an important step forward towards potentially bringing this innovative treatment to patients."

About Study GBCJ

In a 16-week, Phase II study of LY2189265, 262 patients with type 2 diabetes who were suboptimally controlled on at least two oral diabetes medicines were randomized to one of four arms: 1.0 mg of LY2189265 for 16 weeks; 0.5 mg of LY2189265 for four weeks followed by 1.0 mg for 12 weeks; and 1.0 mg of LY2189265 for four weeks followed by 2.0 mg for 12 weeks or placebo. The primary endpoint was glycemic control, as measured by change from baseline in HbA1C; additional endpoints evaluated included changes in fasting serum glucose, solid mixed meal glucose excursion and body weight.

For all do
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... PAUL, Minn. , May 23, 2013  MGC ... Corporation), a global medical technology company, today scheduled a ... second quarter of fiscal year 2013, ended April 30, ... on Thursday, May 30, 2013. The Company will report ... 2013 after the markets close on Thursday, May 30, ...
(Date:5/23/2013)... , May 23, 2013  Hadasit Bio-Holdings Ltd. ... of biotech companies, based on intellectual property developed ... Israel ,s foremost medical research center, today ... Ltd., received significant funding from the Israeli Ministry ... Scientist (OCS) to support product development and advance ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... April 19, 2011 Cumberland Pharmaceuticals Inc. ... focused on hospital acute care and gastroenterology markets, today ... acquire the rights to ifetroban, a new Phase II ... the brand name Hepatoren™ (ifetroban) Injection and is evaluating ...
... 18, 2011 Two lawsuits were filed today on ... have failed.  The cases were filed on behalf of ... DePuy Orthopaedics, Inc., DePuy Inc., DePuy International, Ltd., Johnson ... Johnson & Johnson International, Inc. John David Hart of ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4Recalled DePuy Hip Implant Lawsuits Filed in Fort Worth, Texas 2
(Date:5/24/2013)... Mike Stoler believes that there is much to ... New York. That’s why he hosts “Building New ... And that’s why he invited Robert Glazer, Chief ... largest single specialty practice in the greater New York ... specialists and sub-specialists service communities throughout New York and ...
(Date:5/24/2013)... 24, 2013 According to a May 15, ... Media Leads to Spikes in Plastic Surgery Requests,” ... growing prevalence of facial plastic surgery and cosmetic ... have become keenly aware of the need to look good ... Facebook, Google and even Skype's video chat feature (Go to ...
(Date:5/24/2013)... 24 (HealthDay News) -- About one in five parents ... take up smoking, drinking or illicit drug use, a ... say experts at the Substance Abuse and Mental Health ... are actually one of the most influential forces helping ... "Surveys of teens repeatedly show that parents can ...
(Date:5/24/2013)... May 2013, Paris, France: Transcatheter aortic valve implantation (TAVI) ... early experience based on first results from a multicentre ... "TAVI has become a treatment option for ... data are virtually all from North American or European ... Heart Center, Singapore, told the conference. He explained that ...
(Date:5/24/2013)... 24, 2013 Fit Yummy Mummy, a ... mothers who are trying to get rid of the ... is ideal for women who want to combine exercises ... ’s Stan Stevenson, prompting an investigative review. , ... contains a wide variety of motivational strategies, nutritional plans, ...
Breaking Medicine News(10 mins):Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2
... , LOS ANGELES, Aug. 24 The following statement ... Wilentz Goldman & Spitzer, P.A., Reed Smith LLP, and Thompson Hine LLP ... California, for the County of Los Angeles, Central Civil West: , ... For the Purchase of the Hormone Replacement Therapy Drugs Estratest or Estratest ...
... FARMINGTON HILLS, Mich., Aug. 24 Premier Inc. ... contract to provide RFID Asset Tracking and Management Solutions for ... the country, comprised of more than 1,700 hospitals and 49,000 ... purchasing power. , , "We are ...
... , , , ... California had an opportunity to "become senior citizens" on Friday thanks ... SCAN Health Plan. The award-winning program is a workshop that provides ... senior" through a series of hands-on exercises and sensory ...
... EDEN PRAIRIE, Minn., Aug. 24 NovoLogix, ... it has achieved full accreditation with the Healthcare Network ... Commission (EHNAC). EHNAC,s HNAP accreditation recognizes excellence in health ... standards and HIPAA regulations. , , ...
... Diseases (NIAID), a component of the National Institutes of ... to establish a consortium of human immune profiling research ... receive funding up to $100 million over five yearsis ... and to understand how it changes following infection or ...
... popular social networking tool that was at first merely ... and family, is emerging as a potentially valuable means ... alerts, as described in a feature article in the ... Telemedicine and e-Health , a peer-reviewed journal published by ...
Cached Medicine News:Health News:The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc. 2Health News:The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc. 3Health News:The Rossbacher Law Firm, Hagens Berman Sobol Shapiro LLP, Wilentz Goldman & Spitzer, P.A., Reed Smith LLP and Thompson Hine LLP, Announce the Proposed Settlement of a Class Action Lawsuit Concerning Estratest and Solvay Pharmaceuticals, Inc. 4Health News:USC Gerontology Students Participate in 'Aging Sensitivity Training' Provided by SCAN Health Plan 2Health News:NovoLogix, Inc. Receives EHNAC Healthcare Network Accreditation 2Health News:NovoLogix, Inc. Receives EHNAC Healthcare Network Accreditation 3Health News:NIAID to fund new human immune profiling research centers 2Health News:Twitter and health care -- can a tweet a day keep the doctor away? 2
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
... Codman Sofwire Cable ... bony fixation including sublaminar ... maxillo facial surgery, sternotomy ... cables and a complete ...
Specially designed combination of demineralized bone fibers and demineralized bone cubes that are both osteoinductive and osteoconductive. Packs well into bone defects. Eliminates the need to mix can...
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%....
Medicine Products: